ReviewFrontiers in oncology2022
Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Efficacy of PD-1/PD-L1 inhibitors combined with multi-targeted anti-angiogenic TKIs in advanced or metastatic NSCLC: A meta-analysis based on RCTs.Frontiers in oncology · 2026Pooled it
- Efficacy and Safety of First-Line Treatment Options for Oncogene Wild-Type Lung Adenocarcinoma With Liver Metastases.Cancer medicine · 2026Review
- Article
- [Non-colorectal liver metastases-Indications and treatment approach].Chirurgie (Heidelberg, Germany) · 2026Review
- Evaluation of six clinical prognostic scores in NSCLC patients undergoing first line chemoimmunotherapy.Frontiers in immunology · 2026Article
- Progression and Metastasis of Lung Cancer: Clinical Features, Molecular Mechanisms, and Clinical Managements.MedComm · 2025Review
- Article
- Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer.Cancer research communications · 2025Article
- Reevaluating the role of surgery in lung cancer with liver metastases: a propensity score-matched survival analysis.Discover oncology · 2025Article
- Regulatory T cells in liver metastases: emerging and divergent roles in tumour progression.eGastroenterology · 2025Review
- Survival prognostic nomogram for young metastatic non-small cell lung cancer: a study of the US SEER database and a Chinese cohort.Frontiers in oncology · 2025Article
- Cancer Metastases to the Liver: Mechanisms of Tumor Cell Colonization.Pharmaceuticals (Basel, Switzerland) · 2024Review
- NK cell depletion promotes liver metastasis of lung cancer cells.Acta biochimica et biophysica Sinica · 2024Article
- Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastases.Therapeutic advances in medical oncology · 2024Article
- Nanoparticles overcome adaptive immune resistance and enhance immunotherapyFrontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is a malignant tumor with the highest morbidity and mortality, and more than 75% of patients are diagnosed at an advanced stage. Liver metastases occur in 20% of non-small cell lung cancer patients, and their prognosis are poor. In recent years, immune checkpoint inhibitor monotherapy and combination therapy have made breakthrough progress in advanced Non-small cell lung cancer (NSCLC) patients. However, compared with the overall population, the liver metastases population was an independent prognostic factor for poor immunotherapy response. Whether and how immunotherapy can work in NSCLC patients with liver metastases is a major and unresolved challenge. Although more and more data have been disclosed, the research progress of NSCLC liver metastasis is still limited. How liver metastasis modulates systemic antitumor immunity and the drug resistance mechanisms of the liver immune microenvironment have not been elucidated. We systematically focused on non-small cell lung cancer patients with liver metastases, reviewed and summarized their pathophysiological mechanisms, immune microenvironment characteristics, and optimization of immunotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.